ValuEngine upgraded shares of EnteroMedics (NASDAQ:RSLS) from a sell rating to a hold rating in a research note published on Friday.
Separately, Zacks Investment Research cut shares of EnteroMedics from a buy rating to a hold rating in a research report on Wednesday, November 22nd.
EnteroMedics (NASDAQ:RSLS) traded up $0.04 during trading on Friday, reaching $1.40. 480,300 shares of the company’s stock traded hands, compared to its average volume of 1,609,779. EnteroMedics has a 12 month low of $1.23 and a 12 month high of $30.41.
EnteroMedics Company Profile
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about EnteroMedics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for EnteroMedics Inc. and related companies.